Ex vivo Vitamin D supplementation improves viscoelastic profiles in prostate cancer patients

Hoek, M.J. van den; Schultz, Michelle; Alummoottil, Sajee; Aneck-Hahn, Natalie; Mathabe, Kgomotso; Bester, Janette

doi:10.3233/ch-211353

Cited by 2 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This intricate process influences hundreds of target genes across various tissues and cell types, initially linked to energy homeostasis but also implicated in energy-demanding innate and adaptive immunity. The observed anticancer effects of 25(OH)D are attributed to its direct control of tumor cell differentiation, proliferation, and apoptosis, along with indirect regulation of immune cells within the malignant microenvironment [21][22][23][24][25].…”

Section: Table 2 Association Betweenmentioning

confidence: 99%

Possible non-linear relation between prostate specific antigen and vitamin D: a machine learning study based on cross-section data

Shi,

Yin,

2024

J. Cancer

View full text Add to dashboard Cite

Objective: Due to inconsistent results in earlier investigations regarding the relationship between vitamin D and prostate-specific antigen (PSA), this study was conducted to gain a deeper understanding of the association between vitamin D and PSA. Methods: A total of 7174 male samples with 25(OH)D, PSA, and other variables were obtained from the National Health and Nutrition Examination Survey (NHANES) database. Three models, created through stepwise logistic regression, were employed to examine the dose-response association between PSA and 25(OH)D. Subsequently, restricted cubic spline analysis (RCS) was used to explore the nonlinear association between 25(OH)D and PSA. The study also compared the performance of four machine learning models in predicting PSA levels. Results: The dose-response relationship indicated a negative impact of high 25(OH)D levels on PSA (p for trend 0.05). The odds ratio (OR) of Q4 (7.73 with 95% CI (0.26, 15.76)) was significantly higher than Q1 (6.23 with 95% CI (0.24, 12.57)). OR values in Q2 and Q3 were less than 1 (Q2= 0.57 with 95% CI (-6.37, 8.04) and Q3= 0.26 with 95% CI (-5.94, 6.86)), suggesting a potential protective effect of 25(OH)D on PSA. RCS analysis revealed a U-shaped relationship between blood 25(OH)D levels and PSA, with serum 25(OH)D in the range of 20-134 ng/ml showing a potential decrease in PSA levels. Above this range, an increase in 25(OH)D might elevate PSA levels. Age (2.67 with 95% CI 2.24 to 3.1) and BMI (17.52 with 95% CI 7.65 to 26.32), along with the OR of obesity (10.36 with 95% CI 0.68 to 20.18), were identified as potential PSA risk factors. Among the machine learning models, the random forest algorithm performed the best in predicting PSA levels. Conclusion: This study revealed a U-shaped relationship between 25(OH)D and PSA, with PSA potentially declining when 25(OH)D is between 20 and 134 ng/mL and possibly rising above this range. The random forest method proved effective in both predicting PSA levels and guiding vitamin D dosage.

show abstract

Section: Table 2 Association Betweenmentioning

confidence: 99%

Possible non-linear relation between prostate specific antigen and vitamin D: a machine learning study based on cross-section data

Shi,

Yin,

2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Recently, an increased clot viscosity has been reported in patients with metastatic prostate cancer, indicating a hypercoagulable state, while vitamin D supplementation favorably altered clot viscoelastic profiles. 46 Increased activity of circulating extracellular vesicles exposing TF has been identified as a factor that plays a role in disseminated intravascular coagulation related to prostate cancer. 47…”

Section: Prostate Cancermentioning

confidence: 99%

Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis

Ząbczyk

Undas

2023

Semin Thromb Hemost

View full text Add to dashboard Cite

Cancer is associated with a high risk of venous thromboembolism (VTE) and its recurrence. There is evidence that the prothrombotic fibrin clot phenotype, involving the formation of denser and stiffer clots relatively resistant to lysis, occurs in cancer patients, which is in part related to enhanced inflammation, oxidative stress, and coagulation activation, along with the release of neutrophil extracellular traps, indicating that fibrin-related mechanisms might contribute to cancer-associated thrombosis (CAT). Multiple myeloma and its therapy have been most widely explored in terms of altered fibrin characteristics, but prothrombotic fibrin clot features have also been reported in patients with active solid cancer, including lung cancer and gastrointestinal cancer. Patient-related factors such as advanced age, smoking, and comorbidities might also affect fibrin clot characteristics and the risk of CAT. Prothrombotic fibrin clot features have been shown to predict the detection of cancer in patients following VTE during follow-up. Cancer-specific therapies and anticoagulation can favorably modify the phenotype of a fibrin clot, which may alter the course of CAT. It is unclear whether the fibrin clot phenotype might help identify patients with CAT who are more likely to experience recurrent events. This narrative review summarizes the current knowledge on the role of fibrin clot structure and function in cancer patients in the context of CAT.

show abstract

Ex vivo Vitamin D supplementation improves viscoelastic profiles in prostate cancer patients

Cited by 2 publications

References 41 publications

Possible non-linear relation between prostate specific antigen and vitamin D: a machine learning study based on cross-section data

Possible non-linear relation between prostate specific antigen and vitamin D: a machine learning study based on cross-section data

Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis

Contact Info

Product

Resources

About